Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.

[1]  D. Skowronski,et al.  Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[2]  A. Fernández-Sesma,et al.  Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses , 2015, Journal of Virology.

[3]  P. Palese,et al.  Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. , 2015, Current topics in microbiology and immunology.

[4]  K. To,et al.  Immunogenicity of intradermal trivalent influenza vaccine with topical imiquimod: a double blind randomized controlled trial. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  K. To,et al.  Mice A ( H 1 N 1 ) pdm 09 Virus Infection in BALB / c Responses against Influenza Expedites and Augments Humoral Immune Combination with Influenza Vaccine Toll-Like Receptor 7 Agonist Imiquimod in , 2014 .

[6]  J. Whittle,et al.  Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies , 2013, Nature.

[7]  Wenjun Song,et al.  Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome , 2013, The Lancet.

[8]  F. Ansaldi,et al.  Cross-protection against drifted influenza viruses , 2013, Human vaccines & immunotherapeutics.

[9]  F. Ansaldi,et al.  Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60 , 2013, Human vaccines & immunotherapeutics.

[10]  Kwok-Hung Chan,et al.  Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. , 2012, Vaccine.

[11]  Mark R. Prausnitz,et al.  Effect of Adjuvants on Responses to Skin Immunization by Microneedles Coated with Influenza Subunit Vaccine , 2012, PloS one.

[12]  F. Ansaldi,et al.  Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. , 2012, Vaccine.

[13]  Herman Tse,et al.  Two Years after Pandemic Influenza A/2009/H1N1: What Have We Learned? , 2012, Clinical Microbiology Reviews.

[14]  K. To,et al.  Differences in Antibody Responses of Individuals with Natural Infection and Those Vaccinated against Pandemic H1N1 2009 Influenza , 2011, Clinical and Vaccine Immunology.

[15]  T. Terme,et al.  Safety review: squalene and thimerosal in vaccines. , 2010, Therapie.

[16]  E. Sokal,et al.  Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. , 2010, Vaccine.

[17]  K. To,et al.  Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  L. Sticchi,et al.  Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. , 2010, Vaccine.

[19]  Michele Pellegrini,et al.  Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents , 2010, Clinical & developmental immunology.

[20]  L. Sticchi,et al.  Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. , 2008, Vaccine.

[21]  A. Floreani,et al.  Response of Influenza Vaccines Against Heterovariant Influenza Virus Strains in Adults with Chronic Diseases , 2007, Journal of Clinical Immunology.

[22]  Angus Nicoll,et al.  Avian influenza A (H5N1) infection in humans. , 2005, The New England journal of medicine.

[23]  D. Fleming,et al.  The impact of influenza on the health and health care utilisation of elderly people. , 2005, Vaccine.

[24]  G. Glenn,et al.  Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. , 2005, Vaccine.

[25]  L. Thomsen,et al.  Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. , 2004, Vaccine.

[26]  E. Sandström,et al.  Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. , 2004, Vaccine.

[27]  Wilson Smith,et al.  A Virus obtained from influenza patients , 1933 .